On July 27, 2018, Zhang, Yinsheng; Ren, Jing; Gao, Yong; Zhao, Damin; Zhou, Yu; Wang, Qinglin published a patent.Reference of N-(3-Aminophenyl)acrylamide The title of the patent was Bruton’s tyrosine kinase (BTK) inhibitor for preparing drugs for preventing or treating BTK-mediated diseases. And the patent contained the following:
The inhibitor has the structural formula I, wherein R1 includes hydrogen, halogen, etc.; R2 includes hydrogen, hydroxyl, etc., L includes imino, oxygen, etc.. The inhibitor includes N-(3-((2-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide, N-(3-((2-((2-hydroxy-2,3-dihydrobenzo[d][1,2]oxaborol-6-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide, etc., or its pharmaceutically acceptable salts. A pharmaceutical composition comprises the inhibitor and its pharmaceutically acceptable salts, and is used in preparing drugs for preventing or treating BTK-mediated diseases. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Reference of N-(3-Aminophenyl)acrylamide
The Article related to acrylamide preparation bruton tyrosine kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of N-(3-Aminophenyl)acrylamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics